RCT: A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma
15 Feb, 2021 | 00:32h | UTCA comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial – The Lancet (link to abstract – $ for full-text)
Commentary: Cabozantinib most effective treatment for metastatic papillary kidney cancer – MedicalXpress